CastellaniMR, SeregniE, MaccauroM, ChiesaC, AlibertiG, OrunesuE, BombardieriE. 2008. MIBG for diagnosis and therapy of medullary thyroid carcinoma: is there still a role?Q J Nucl Med Mol Imaging, 52:430–440.
2.
ItenF, MüllerB, SchindlerC, RochlitzC, OertliD, MäckeHR, Müller-BrandJ, WalterMA. 2008. Response to [90Yttrium-DOTA]-TOC treatment is associated with long-term survival benefit in metastasized medullary thyroid cancer: a phase II clinical trial. Clin Cancer Res, 13:6696–6702.
3.
ChatalJF, CampionL, Kraeber-BodéréF, BardetS, VuillezJP, CharbonnelB, RohmerV, ChangCH, SharkeyRM, GoldenbergDM, BarbetJ. 2006. Survival improvement in patients with medullary thyroid carcinoma who undergo pretargeted anti-carcinoembryonic-antigen radioimmunotherapy: a collaborative study with the French Endocrine Tumor Group. J Clin Oncol, 24:1705–1711.
4.
KloosRT, EngC, EvansDB, FrancisGL, GagelRF, GharibH, MoleyJF, PaciniF, RingelMD, SchlumbergerM, WellsSAJr. 2009. Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid, 19:565–612.
